SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:35bd6e2b-c009-4a28-832a-f639bb1a8c5e"
 

Search: onr:"swepub:oai:lup.lub.lu.se:35bd6e2b-c009-4a28-832a-f639bb1a8c5e" > Hypophosphataemia f...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease (PHOSPHARE-IBD) : A randomised clinical trial

Zoller, Heinz (author)
Medical University of Innsbruck
Wolf, Myles (author)
Duke Clinical Research Institute (DCRI)
Blumenstein, Irina (author)
University Hospital Frankfurt
show more...
Primas, Christian (author)
Medical University of Vienna
Lindgren, Stefan (author)
Lund University,Lunds universitet,Gastroenterologi,Forskargrupper vid Lunds universitet,Gastroenterology,Lund University Research Groups,Skåne University Hospital
Thomsen, Lars L. (author)
Pharmacosmos A/S
Reinisch, Walter (author)
Medical University of Vienna
Iqbal, Tariq (author)
New Queen Elizabeth Hospital
show less...
 (creator_code:org_t)
2022-09-09
2023
English.
In: Gut. - : BMJ. - 0017-5749 .- 1468-3288. ; 72:4, s. 644-653
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Objective: Intravenous iron - a common treatment for anaemia and iron deficiency due to inflammatory bowel disease (IBD) - can cause hypophosphataemia. This trial compared the incidence of hypophosphataemia after treatment with ferric carboxymaltose (FCM) or ferric derisomaltose (FDI). Design: This randomised, double-blind, clinical trial was conducted at 20 outpatient hospital clinics in Europe (Austria, Denmark, Germany, Sweden, UK). Adults with IBD and iron deficiency anaemia (IDA) were randomised 1:1 to receive FCM or FDI at baseline and at Day 35 using identical haemoglobin- and weight-based dosing regimens. The primary outcome was the incidence of hypophosphataemia (serum phosphate <2.0 mg/dL) at any time from baseline to Day 35 in the safety analysis set (all patients who received ≥1 dose of study drug). Markers of mineral and bone homeostasis, and patient-reported fatigue scores, were measured. Results: A total of 156 patients were screened; 97 (49 FDI, 48 FCM) were included and treated. Incident hypophosphataemia occurred in 8.3% (4/48) FDI-treated patients and in 51.0% (25/49) FCM-treated patients (adjusted risk difference: -42.8% (95% CI -57.1% to -24.6%) p<0.0001). Both iron formulations corrected IDA. Patient-reported fatigue scores improved in both groups, but more slowly and to a lesser extent with FCM than FDI; slower improvement in fatigue was associated with greater decrease in phosphate concentration. Conclusion: Despite comparably effective treatment of IDA, FCM caused a significantly higher rate of hypophosphataemia than FDI. Further studies are needed to address the longer-term clinical consequences of hypophosphataemia and to investigate mechanisms underpinning the differential effects of FCM and FDI on patient-reported fatigue.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Gastroenterologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)

Keyword

anemia
IBD
iron deficiency

Publication and Content Type

art (subject category)
ref (subject category)

Find in a library

  • Gut (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view